Mariantonietta Capristo

Mariantonietta Capristo

Auto-generated profile, based on publicly available information

Mariantonietta Capristo

IRCCS Istituto delle Scienze Neurologiche di Bologna, UOC Clinica Neurologica, Bologna, Italy

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 December 2009 in Human Molecular Genetics
Verified
Journal Article
Open access
PDF file
APAnna Maria Porcelli
Anna Maria Porcelli
AGAnna Ghelli
Anna Ghelli
CCClaudio Ceccarelli
Claudio Ceccarelli
MLMartin Lang
Martin Lang
GCGiovanna Cenacchi
Giovanna Cenacchi
GGGiuseppe Gasparre
Giuseppe Gasparre
We previously showed that disruptive complex I mutations in mitochondrial DNA are the main genetic hallmark of oncocytic tumors of the thyroid and kidney. We here report a high frequency of homoplasmic disruptive mutations in a large panel of oncocytic pituitary and head-and-neck tumors. The presence of such mutations implicates disassembly of respiratory complex I in vivo which in turn contributes to the inability of oncocytic tumors to stabilize HIF1α and to display pseudo-hypoxia. By utilizing transmitochondrial cytoplasmic hybrids (cybrids), we induced the shift to homoplasmy of a truncating mutation in the mitochondria-coded MTND1 gene. Such shift is associated with a profound metabolic impairment leading to the imbalance of α-ketoglutarate and succinate, the Krebs cycle metabolites which are the main responsible for HIF1α stabilization. We conclude that the main hallmarks of oncocytic transformation, namely the occurrence of homoplasmic disruptive mutations and complex I disassembly, may explain the benign nature of oncocytic neoplasms through lack of HIF1α stabilization.

29 September 2011 in Cancer Research
Verified
Journal Article
Open access
PDF file
GGGiuseppe Gasparre
Giuseppe Gasparre
IKIvana Kurelac
Ivana Kurelac
MCMariantonietta Capristo
Mariantonietta Capristo
Luisa IommariniLuisa Iommarini
Luisa Iommarini
AGAnna Ghelli
Anna Ghelli
APAnna Maria Porcelli
Anna Maria Porcelli
The oncogenic versus suppressor roles of mitochondrial genes have long been debated. Peculiar features of mitochondrial genetics such as hetero/homoplasmy and mutation threshold are seldom taken into account in this debate. Mitochondrial DNA (mtDNA) mutations generally have been claimed to be protumorigenic, but they are also hallmarks of mostly benign oncocytic tumors wherein they help reduce adaptation to hypoxia by destabilizing hypoxia-inducible factor-1α (HIF1α). To determine the influence of a disassembling mtDNA mutation and its hetero/homoplasmy on tumorigenic and metastatic potential, we injected mice with tumor cells harboring different loads of the gene MTND1 m.3571insC. Cell cultures obtained from tumor xenografts were then analyzed to correlate energetic competence, apoptosis, α-ketoglutarate (α-KG)/succinate (SA) ratio, and HIF1α stabilization with the mutation load. A threshold level for the antitumorigenic effect of MTND1 m.3571insC mutation was defined, above which tumor growth and invasiveness were reduced significantly. Notably, HIF1α destabilization and downregulation of HIF1α-dependent genes occurred in cells and tumors lacking complex I (CI), where there was an associated imbalance of α-KG/SA despite the presence of an actual hypoxic environment. These results strongly implicate mtDNA mutations as a cause of oncocytic transformation. Thus, the antitumorigenic and antimetastatic effects of high loads of MTND1 m.3571insC, following CI disassembly, define a novel threshold-regulated class of cancer genes. We suggest these genes be termed oncojanus genes to recognize their ability to contribute either oncogenic or suppressive functions in mitochondrial settings during tumorigenesis. Cancer Res; 71(19); 6220–9. ©2011 AACR.

24 October 2013 in Human Molecular Genetics
Verified
Journal Article
Open access
PDF file
Luisa IommariniLuisa Iommarini
Luisa Iommarini
IKIvana Kurelac
Ivana Kurelac
MCMariantonietta Capristo
Mariantonietta Capristo
MCMaria Antonietta Calvaruso
Maria Antonietta Calvaruso
VGValentina Giorgio
Valentina Giorgio
APAnna Maria Porcelli
Anna Maria Porcelli
Mitochondrial DNA mutations are currently investigated as modifying factors impinging on tumor growth and aggressiveness, having been found in virtually all cancer types and most commonly affecting genes encoding mitochondrial complex I (CI) subunits. However, it is still unclear whether they exert a pro- or anti-tumorigenic effect. We here analyzed the impact of three homoplasmic mtDNA mutations (m.3460G>A/MT-ND1, m.3571insC/MT-ND1 and m.3243A>G/MT-TL1) on osteosarcoma progression, chosen since they induce different degrees of oxidative phosphorylation impairment. In fact, the m.3460G>A/MT-ND1 mutation caused only a reduction in CI activity, whereas the m.3571insC/MT-ND1 and the m.3243A>G/MT-TL1 mutations induced a severe structural and functional CI alteration. As a consequence, this severe CI dysfunction determined an energetic defect associated with a compensatory increase in glycolytic metabolism and AMP-activated protein kinase activation. Osteosarcoma cells carrying such marked CI impairment displayed a reduced tumorigenic potential both in vitro and in vivo, when compared with cells with mild CI dysfunction, suggesting that mtDNA mutations may display diverse impact on tumorigenic potential depending on the type and severity of the resulting oxidative phosphorylation dysfunction. The modulation of tumor growth was independent from reactive oxygen species production but correlated with hypoxia-inducible factor 1α stabilization, indicating that structural and functional integrity of CI and oxidative phosphorylation are required for hypoxic adaptation and tumor progression.

4 August 2016 in Annals of Neurology
Verified
Journal Article
Closed access
PDF file
Roberto De GiorgioRoberto De Giorgio
Roberto De Giorgio
LPLoris Pironi
Loris Pironi
RRRita Rinaldi
Rita Rinaldi
EBElisa Boschetti
Elisa Boschetti
LCLeonardo Caporali
Leonardo Caporali
APAntonio Daniele Pinna
Antonio Daniele Pinna

18 March 2013 in Cancer & Metabolism
Verified
Journal Article
Open access
PDF file
CCClaudia Calabrese
Claudia Calabrese
Luisa IommariniLuisa Iommarini
Luisa Iommarini
IKIvana Kurelac
Ivana Kurelac
MCMaria Antonietta Calvaruso
Maria Antonietta Calvaruso
MCMariantonietta Capristo
Mariantonietta Capristo
APAnna Maria Porcelli
Anna Maria Porcelli
Background: Aerobic glycolysis, namely the Warburg effect, is the main hallmark of cancer cells. Mitochondrial respiratory dysfunction has been proposed to be one of the major causes for such glycolytic shift. This hypothesis has been revisited as tumors appear to undergo waves of gene regulation during progression, some of which rely on functional mitochondria. In this framework, the role of mitochondrial complex I is still debated, in particular with respect to the effect of mitochondrial DNA mutations in cancer metabolism. The aim of this work is to provide the proof of concept that functional complex I is necessary to sustain tumor progression. Methods: Complex I-null osteosarcoma cells were complemented with allotopically expressed complex I subunit 1 (MT-ND1). Complex I re-assembly and function recovery, also in terms of NADH consumption, were assessed. Clones were tested for their ability to grow in soft agar and to generate tumor masses in nude mice. Hypoxia levels were evaluated via pimonidazole staining and hypoxia-inducible factor-1α (HIF-1α) immunoblotting and histochemical staining. 454-pyrosequencing was implemented to obtain global transcriptomic profiling of allotopic and non-allotopic xenografts. Results: Complementation of a truncative mutation in the gene encoding MT-ND1, showed that a functional enzyme was required to perform the glycolytic shift during the hypoxia response and to induce a Warburg profile in vitro and in vivo, fostering cancer progression. Such trigger was mediated by HIF-1α, whose stabilization was regulated after recovery of the balance between α-ketoglutarate and succinate due to a recuperation of NADH consumption that followed complex I rescue. Conclusion: Respiratory complex I is essential for the induction of Warburg effect and adaptation to hypoxia of cancer cells, allowing them to sustain tumor growth. Differently from other mitochondrial tumor suppressor genes, therefore, a complex I severe mutation such as the one here reported may confer anti-tumorigenic properties, highlighting the prognostic values of such genetic markers in cancer.

1 September 2017 in Mitochondrion
Verified
Journal Article
Closed access
LCLeonardo Caporali
Leonardo Caporali
AMAlessandra Maresca
Alessandra Maresca
MCMariantonietta Capristo
Mariantonietta Capristo
VDValentina Del Dotto
Valentina Del Dotto
FTFrancesca Tagliavini
Francesca Tagliavini
Valerio CarelliValerio Carelli
Valerio Carelli